This multicenter RCT compared SVF-enriched autologous fat grafting (AFG) versus standard AFG in 312 patients with bilateral breast hypoplasia, asymmetry, ptosis/pseudoptosis, or post-lumpectomy defects across six centers (January 2021–March 2025), with primary endpoint of MRI-based volumetric graft retention at 12 months.
SVF-enriched AFG achieved significantly higher graft retention at 12 months (71.8% ± 11.2% vs. 56.4% ± 13.7%; p < 0.001) and 24 months (66.2% ± 12.0% vs. 49.8% ± 14.1%; p < 0.001), with higher BREAST-Q satisfaction scores at both timepoints; fat necrosis, oil cyst rates, and suspicious MRI findings were similar between groups.
- Heterogeneous indications (hypoplasia, asymmetry, ptosis, post-lumpectomy) were pooled, which may obscure condition-specific effects. - SVF processing protocols and graft volumes may have varied across the six centers, potentially introducing procedural inconsistency. - Longer-term retention and oncologic safety beyond 28 months are not yet reported.
SVF enrichment improves fat graft retention by ~15 percentage points at 12 months without adding radiologic or clinical complications, making it a viable upgrade to standard AFG for breast reconstruction and augmentation. Clinicians should weigh the additional processing step against meaningfully better volume persistence and patient satisfaction.
Explore related topics